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Abstract. HIV-associated PBL is an AIDS-defining cancer, classified by WHO as a distinct entity of 
aggressive DLBCL. To date less than 250 cases have been published, of them 17 are pediatric. The 
pathogenesis of this rare disease is related to immunodeficiency, chronic immune stimulation and 
EBV. Clinically  is  a rapid growing destructive disease  mainly  involving  the oral cavity even if 
extraoral and extranodal sites are not infrequent. The diagnosis requires tissue mass or lymph node 
biopsy and core needle or fine needle biopsy is acceptable only for difficult access sites. Classically 
immunophenotype is CD45, CD20, CD79a negative and CD38, CD138, MUM1 positive, EBER and 
KI67  is  >80%.    Regarding  the  therapy,  standard  treatment  is,  usually,  CHOP  or  CHOP-like 
regimens while more intensive regimens as CODOX-M/IVAC or DA-EPOCH are possible options. 
Use of cART is  recommended during chemotherapy, keeping in mind the possible overlapping 
toxicities.  Rituximab  is  not  useful  for  this  CD20  negative  disease  and  CNS  prophylaxis  is 
mandatory.  Intensification  with  ABMT  in  CR1  may  be  considered  for  fit  patients.  For 
refractory/relapsed patients, therapy is, usually, considered palliative, however, in chemo-sensitive 
disease, intensification + ABMT or new drugs as Bortezomib may be considered. Factors affecting 
outcome are achieving complete remission, PS, clinical stage, MYC, IPI score. Reported median 
PFS  ranges  between  6-7  months  and  median  OS  ranges  between  11-13  months.  Long  term 
survivors are reported but mostly in pediatric patients.  Finally, due to the scarcity of data on this 
subtype of NHL we suggest that the diagnosis and the management of HIV-positive PBL patients 
should be performed in specialized centers.  
History. This particular variant of diffuse large-B-cell 
lymphoma  (DLBCL)  was  first  recognized  and 
described as a new entity in 1992 by Stein in the first 
edition of the textbook “Neoplastic Hematopathology”.
 
1  Delecluse  and  Stein  in  1997,  drawing  from  the 
consultation files of the lymphoma reference center at 
the Benjamin Franklin Hospital in Berlin, published the 
first case series of plasmablastic lymphoma (PBL) in 
HIV-positive  (HIV+)  patients  in  whom  PBL  was 
mainly located in the oral cavity.
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Nomenclature.  The  term  plasmablastic  lymphoma 
(PBL) refers to a rare and distinct entity classified by 
the  World  Health  Organization  (WHO)  as  an 
aggressive  subtype  of  DLBCL,  characterized  by  a 
“diffuse proliferation of large neoplastic cells most of 
which  resemble  B-cell  immunoblasts,  but  in  which 
tumor  cells  have  a  plasma  cell  immunophenotype”.
3 
This disease is strongly associated with HIV infection, 
however it may also arise with other immunodeficiency 
states such as organ transplant patients, the elderly, and 
in  immunocompetent  individuals.
4,5  HIV-associated 
PBL  is  included  in  the  list  of  serious  and  life-
threatening  diseases  that  occur  in  HIV-positive 
individuals  considered  as  "AIDS-defining"  illnesses.
6 
When a person gets one of these illnesses, he or she is 
diagnosed  with  the  advanced  stage  of  HIV  infection 
known as AIDS. 
 
Incidence  and  Temporal  Trends.  Since  the 
introduction  of  combination  antiretroviral  therapy 
(cART),  the  incidence  of  AIDS-related  lymphomas 
(ARLs), initially very high with 449 cases per 100.000 
person-years  (1996-2000  calendar  period)  and 
standardized  incidence  ratio  (SIR)  of  13.2,  has 
dramatically declined. Nowadays, the incidence is near 
194  cases  per  100.000  person-years  (2006-2010 
calendar period) with SIR of  10.0.
7 DLBCL remains 
the main type of cancer that develops in HIV-positive 
patients.
8 
The incidence of HIV-associated PBL accounts for 
approximately 2% of all ARLs. However because of 
the rarity, the exact incidence and temporal trends are 
unknown.
9  Several  case reports  and case  series  have 
been published to date, accounting for no more than 
250  cases.  In  a  Pubmed  search  using  the  keywords 
“plasmablastic”  and  “lymphoma”  and  “HIV”,  313 
articles  were  published  between  2000  and  2009  (10 
years), and 234 articles between 2010 and today (<5 
years). It is unclear if the actual incidence of PBL has 
increased  in  recent  years.  This  apparent  increase  in 
published  case  reports  and  series  might  just  be  a 
reflection  of  an  increased  awareness  of  PBL  among 
clinicians. 
 
Pathogenesis.  The  pathogenesis  of  PBL  HIV-
associated is poorly understood and determined by the 
complexity  of  biological  interplays  between  HIV-
related  immunodeficiency,  genetic  cellular 
abnormalities,  co-infecting  oncogenic  viruses  and 
chronic immune activation. In defining diagnostic and 
treatment  strategies,  it  is  of  utmost  importance  to 
understand not only the molecular mechanism of viral 
carcinogenesis but also the host counterpart in term of 
immunologic status of the patient.
10 The contribution of 
HIV to PBL pathogenesis might develop through four 
main mechanisms: 1) the duration and the degree of 
immunodeficiency  or  immunosuppression;  2)  the 
induction of chronic antigenic stimulation leading to a 
chronic B-cell proliferation/exhaustion; 3) the loss of 
immune control of oncogenic herpesvirus as EBV; and 
4)  an  incomplete  immune  reconstitution  or  factors 
unrelated to immune dysfunction.
11 
 
Degree and duration of immunodeficiency. Time spent 
with higher viral load and lower CD4 counts plays an 
important  role  in  the  development  of  ARLs.  HIV-
positive PBL patients encompassing the pre- and post-
ART  eras  have  an  average  CD4  count  at  lymphoma 
presentation around 200 cell/mm3 and an average viral 
load  of  250.000  copies/mL.
12  The  reported  average 
duration from HIV diagnosis to PBL diagnosis is 8.9 
years.
13  
 
Chronic  antigenic  stimulation.  HIV  infection  is 
characterized by chronic immune activation due to: 1) 
a persistent antigenic stimulation by viral HIV proteins 
or other viral co-infections (e.g. Cytomegalovirus and 
microbial product after microbial translocation in the 
gut); 2) the presence of a chronic general unresolved 
inflammatory state. This state can lead to a polyclonal 
B-cell expansion/dysfunction promoting the emergence 
of monoclonal B-cell, and to an abnormal production 
of stimulatory cytokines such IL-6.
14 
 
Virology.  HIV-associated  ARL,  including  PBL,  is 
strongly related to Epstein-Barr virus (EBV) infection, 
and near 80% of these lymphoma cells express EBNA1 
and  EBV-encoded  RNAs  detected  using  an  in  situ 
hybridization  technique,  representing  then  a  type  I 
latency  pattern.
10-15  Similarly,  plasmacytoid  Burkitt 
lymphomas  express  the  same  type  I  EBV  latency 
pattern.  In  contrast  in  EBV-associated    DLBCL 
immunoblastic lymphoma, tumour cells express EBV-
encoded LMP1 (indicating a type II latency pattern). 
Of  note,  a  subset  of  DLBCL  may  have  a  type  III 
latency pattern as proved by the additional expression 
of the EBNA2 protein.
10 
 
Molecular Genetics. The potential role of MYC gene 
rearrangements is currently unclear. This translocation 
mostly  occurs  in  the  context  of  complex  karyotype 
abnormalities  involving  as  a  common  partner  in 
translocation  the  immunoglobulin  gene.  Of  note  in 
contrast of most lymphomas with MYC rearrangement 
that have a germinal center phenotype, PBL HIV+ have 
a  typical  postgerminal  center  profile,  suggesting  a 
distinct role in the pathogenesis.
10 Of clinical interest, 
this translocation have been identified in near 50% of 
patients HIV+ with PBL and has been associated with 
worse outcome.
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Clinical Presentations and Features. HIV-associated 
PBL is characterized for its predilection of involving 
the  oral  cavity  as  originally  described.  Nevertheless, 
near  45%  of  cases  have  been  reported  in  extra-oral 
sites, including gastrointestinal tract, skin, soft tissue, 
heart,  mediastinum,  retroperitoneum,  liver,  lungs, 
testes,  vulva,  parotid  gland,  breast,  central  nervous 
system (CNS), lymph nodes and bone marrow.
13-17 This 
lymphoma  demonstrates  a  male  predominance  (4:1) 
with a median age at presentation of 40 years, being the 
disease  the  initial  presentation  of  HIV  infection  in 
approximately 5% of the cases. Of note, also pediatric 
cases have been reported. Most patients present with 
rapid  growing,  sometimes  destructive,  disease  in 
advanced  clinical  stage  elevated  LDH  and  B 
symptoms.
18     
 
Diagnosis.  Diagnosis  requires  a  properly  evaluated 
tissue biopsy of mass lesion or lymph node. Excisional 
biopsy  is  the  gold  standard;  however,  because 
frequently the site of the disease is difficult to access, 
core needle biopsy and fine needle aspiration (FNA) 
may  be  performed  in  conjunction  with  appropriate 
ancillary techniques for the differential diagnosis (i.e. 
flow  cytometry,  PCR  for  IgH  and  TCR  gene 
rearrangements,  FISH  for  major  translocations, 
immunohistochemistry, cytogenetic studies, etc).  
 
Morphology.  PBL  is  characterized  by  monomorphic 
cellular proliferation of round to oval-shaped cells with 
either  centrally  or  eccentrically  placed  nuclei  and 
abundant eosinophilic cytoplasm in a diffuse sheet-like 
and  cohesive  growth  pattern  (Figure  1).  Apoptotic 
bodies and mitotic figures are frequent, and tangible-
body  macrophages  are  easily  detectable  leading  to  a 
starry-sky appearance.
1-2 
 
Immunophenotype.  PBL  is  a  high-grade  B-cell 
lymphoma that arises from post-germinal center B-cell 
and  usually  express  the  characteristic 
immunophenotype  of  plasmacytoid  terminally 
differentiated B-cell. As plasmablasts acquire plasma-
cell markers (i.e. VS38c, CD38, MUM1/IRF4, CD138, 
EMA),  they  lose  the  leukocyte  common  antigen 
(CD45) and their B-cell markers CD20, CD79a, PAX5, 
and  a  high  proliferation  rate  reflected  by  Ki67 
expression  >80%.  (Figure  1).  Cytoplasmic 
immunoglobulins are expressed in near 70% of cases. 
Interestingly,  these  lymphomas  might  express 
epithelial  and  endothelial  markers  such  EMA  and 
CD31, posing some problems in differential diagnosis 
with poorly differentiated solid tumors.
10 Recently, an 
immunohistochemistry stain for PRDM1/BLIMP1 and 
XBP1 have been proposed to identify PBL, however 
this finding remains investigational.
11 
Virology and genetics. HIV-associated PBL is closely 
linked to EBV infection, and more than 80% of PBL 
cells  express  EBV-encoded  RNA  (EBER-ISH). 
(Figure  1).  MYC  rearrangements,  like  other  high-
grade B-cell lymphomas of aggressive type, are found 
in  near  50%  and  frequently  correlated  with  EBV 
infection and worse prognosis. Molecular analysis of 
BCL2  and  BCL6  are,  usually,  negative.
12,15  The 
presence  of  HHV8  within  the  sample  can  indicate  a 
different condition called HHV8-positive PBL arising 
from multicentric Castleman’s disease.
17 
 
Clinical  evaluation  and  staging.  Patients  with 
suspected HIV-associated PBL should have a complete 
medical  history,  a  careful  physical  examination  of 
node-bearing  areas  including  Waldeyer’s  ring,  skin, 
liver  and  spleen,  and  an  adequate  evaluation  of 
performance status and the presence of B symptoms. 
Laboratory evaluation should include a complete blood 
count,  chemistry  and  immunoglobulins  profile  with 
kappa and lambda evaluation in plasma and urine. It is 
of  utmost  importance  to  evaluate  renal,  hepatic  and 
cardiac  functions  prior  intensive  chemotherapy  and 
patients should undergo echocardiographic evaluation 
of cardiac function because of the anthracycline–based 
chemotherapy,  and  gastrointestinal  endoscopy  if 
symptoms or lesions of suspicious on imaging studies 
are  present.  Pregnancy  testing  in  women  of 
childbearing  age  is  mandatory  if  chemotherapy  is 
planned. 
Imaging  studies  should  include  whole  body 
contrast-enhanced CT and an MRI of the head.  FDG-
PET in HIV associated lymphoma have a limitation in 
interpretation  because  the  results  can  be  confounded 
with inflammation and infections typically present in 
those patients.
26,.27 A bone marrow biopsy and aspirate 
should be performed as involvement by PBL is found 
in up 25% of patients.
15 Because PBL patients HIV+ 
are at high risk for presentation or recurrence in the 
CNS,  particularly  meninges,  a  lumbar  puncture 
analyzing  the  cerebrospinal  fluid  by  flow  cytometry, 
cytology and molecular studies should be performed to 
check for leptomeningeal lymphoma. The Ann Arbor 
system  is  the  most  commonly  used  for  staging 
purposes. We recommend the use of the International 
Prognostic Index (IPI) for risk-stratification. 
 
Differential diagnosis. The morphological differential 
diagnosis  includes  poorly  differentiated  and 
undifferentiated carcinoma, lymphoblastic lymphoma, 
plasmablastic  variant  of  Burkitt’s  lymphoma  and 
anaplastic  plasmacytoma.  Differentiating  PBLs  from 
anaplastic  plasmacytoma  may  be  a  diagnostic 
challenge. In fact highly aggressive plasma cell  Mediterr J Hematol Infect Dis 2014; 6: Open Journal System   
 
 
Figure  1.  H&E:  Large  lymphoid  cells  with  plasmablastic  features,  haematoxylin  and  eosin  stain  (medium  and  high  resolution); 
IRF4/MUM1: multiple myelomas oncogene 1/interferon regulatory factor 4; EMA: epithelial membrane antigen; KI-67%.  marker of  the 
growth  fraction;  EBER,  Epstein-Barr  virus-encoded  RNA;  CD20,  cluster  of  differentiation  20  (B-lymphocyte  antigen);BCL6,  B-cell 
lymphoma 6; CD138, cluster of differentiation 138 (syndecan-1) 
 
myeloma  and  extramedullary  plasmacytoma  may 
contain a predominance of plasmablasts with a similar 
immunophenotype  to  PBL,  but  myeloma  cells  are, 
usually,  EBV  negative.  The  presence  high  level  of 
serum monoclonal proteins, and bone involvement with 
radiographically  evident  lytic  lesions  favor  the 
diagnosis  of  myeloma  rather  than  PBL.  Plasma  cell 
myeloma and plasmacytoma are very rare in the setting 
of HIV, and in the few cases reported in the literature a 
previous  progression  from  MGUS  was  reported.
21-23 
However,  the  presence  of  MGUS  is  frequently 
encountered in patients at HIV presentation, reflecting 
dysregulation  of  the  immune  system  due  to  the 
presence of HIV, but almost always MGUS disappears 
when  viral  load  becomes  undetectable
.  24-25  Other 
potential differential diagnoses include CD20-negative 
aggressive  lymphomas  such  as  solid  or  extracavitary 
primary effusion lymphoma and ALK+ DLBCL. 
 
HIV  disease  status.  A  detailed  comprehensive 
evaluation  of  HIV  disease  must  be  performed 
including;  duration  of  HIV  infection,  mode  of  HIV 
transmission, prior opportunistic infections, CD4+ cell 
count and viral load at HIV diagnosis and at diagnosis 
of lymphoma.
10 A strategic history of HIV viral control 
and  antiretroviral  treatment  with  regards  to  HIV 
mutation and resistance should be assessed. In addition, 
information  about  HCV,  HBV,  tuberculosis,  malaria, 
leishmaniasis coinfections and EBV, HHV8, CMV and 
sexually transmitted diseases are necessary for clinical 
management and therapeutic decisions.
14 
 
Fertility  preservation  counselling  and  management. 
Fertility  preservation  is  an  essential  consideration  of 
cancer  management.  Because  HIV-associated  PBL 
frequently occur  in young patients, this issue should be 
discussed  as  early  as  possible  during  treatment 
planning. For male patients, sperm banking should be 
planned  before  treatment  initiation.  Semen Mediterr J Hematol Infect Dis 2014; 6: Open Journal System   
 
cryopreservation  is  recommended  independently  of 
patient’s  age,  according  to  their  wishes  of  future 
paternity.  Embryo  or  oocyte  cryopreservation  can 
address  the  sterility  chemo-radiotherapy  induced  in 
women,  this  method  it  actually  the  gold  standard  to 
preserve  female  fertility,  but  requires  in  vitro 
fertilization procedure. Freezing ovarian tissue before 
treatment may be an option (the tissue is harvested with 
laparoscopy  and  re-implanted  after  thawing  in  the 
pelvis when needed) but is an experimental method.
28 
 
 
Management. 
First  –line  treatment.  The  treatment  of  PBL  HIV-
associated  has  not  been  standardized  as  prospective 
studies to define a standard of care are lacking. It is a 
common  practice  to  start  patients  on  combination 
chemotherapy.  In  the  recently  updated  National 
Comprehensive  Cancer  Network  guidelines,  the 
recommendation is to treat HIV+ PBL with intensive 
regimens as CODOX-M/IVAC, Hyper-CVAD, or DA-
EPOCH as possible options. Standard CHOP seems not 
an  adequate  therapy.
29  However,  CHOP  therapy  is 
often  given  to  treat  PBL.
14,20  Intensification  of 
induction chemotherapy with autologous bone marrow 
transplantation (ABMT), thought to be a good option in 
HIV-negative patients with chemosensitive disease, has 
also  been  shown  to  be  feasible  also  in  HIV+ 
patients.
9,30  Of  note,  HIV  infection  alone  should  not 
preclude an attempt to obtain stem cell in candidates 
for  ABMT.  Chemotherapy  plus  G-SCF  seems  to 
mobilize better than G-CSF alone, and at least 3g/m
2 of 
cyclophosphamide is recommended.
31 
 
New  drugs.  Because  PBL  shares  many  morphologic 
and  immunophenotypic  traits  with  plasmablastic 
myelomas  some  studies  have  reported  that  the 
proteasome  inhibitor  bortezomib  alone  or  in 
combination  with  chemotherapy  may  have  an 
antitumor effect in PBL, blocking NFKB or overcoming 
the  typical  chemoresistance  of  this  disease.  For  the 
same reason, the use of lenalidomide has been reported 
in  PBL.  This  well-known  immunomodulatory  agent 
has  proved  to  be  effective  as  a  single  agent  in 
aggressive relapsed or refractory HIV-negative patients 
with  non-Hodgkin’s  lymphoma  by  enhancing  the 
immune system, with robust response rates. However, 
the  reported  outcome,  at  the  case  report  level,  with 
these new agents are transient.
32,33 Due to the lack of 
CD20 expression, the use of the anti-CD20 monoclonal 
antibody  rituximab,  is  unlikely  to  be  of  benefit, 
however it could be considered if partial expression of 
CD20 is detected within the malignant cells.   
 
Refractory or relapsed patients. Treatment in patients 
with  refractory  or  relapsed  HIV-associated  PBL  is 
considered palliative although some cases of long-term 
survival  have  been  described.  In  general,  a  more 
intensive  chemotherapy  is  planned  for  relapsed 
patients,  and  for  fit  patients  intensification  of 
chemotherapy with AMBT may be an option. Multiple 
reports from single centers or cooperative groups have 
been published. Effectiveness of such therapy was not 
significantly different between HIV-positive and HIV-
negative  patients,  in  term  of  treatment-related 
mortality,  opportunistic  infections,  immune  recovery, 
and OS. Of note, allogeneic BMT is a more limited 
option in HIV-positive relapsed PBLs.
9,30 
 
Specific Treatment Considerations.  
Supportive therapy. More vigorous supportive care is 
necessary  for  HIV-infected  patients  than  in  patients 
who  are  not  infected  with  HIV,  and  antibacterial, 
antifungal, and antiviral prophylaxis may be offered in 
accordance with current guidelines.
30,32 Patients should 
be  screened  for  hepatitis  B  infection  and  antiviral 
prophylaxis initiated if indicated. CD4 count cell must 
be regularly evaluated during and after chemotherapy, 
and cotrimoxazole prophylaxis strongly recommended 
when the CD4 cell count falls below 200 cell/ml for 
prevention of Pneumocystis pneumonia.  
 
CNS prophylaxis. Patients with PBLs HIV are at  risk 
of  for  leptomeningeal  disease.  Considering  this  high 
risk of progression during the treatment or recurrence 
during the remission, the use of intrathecal prophylaxis 
is  considered  a  mandatory  part  of  the  systemic 
treatment.
34
  Controlled  studies  on  this  field  are  not 
available,  so  the  standard  procedure  has  not  been 
defined.  However,  intrathecal  methotrexate  or 
cytarabine  are  administered  at  each  cycle  of 
chemotherapy, based upon institutional preference.
35 
 
Use  of  cART  during  chemotherapy.  Most  guidelines 
recommend,  on  the  basis  of  different  meta-analyses, 
the use of cART during chemotherapy.  However, it is 
important  to  keep  in  mind  the  possible  overlapping 
toxicity,  pharmacokinetic  interactions,  and  adherence 
problems,  to  avoid  stop  and  start  cART  strategy 
because  of  HIV  drug  resistance.
10,14  Although  no 
prospective  studies  have  been  performed,  and 
controversies  abound,  the  addition  of  cART  to 
chemotherapy  seems  to  have  a  favorable  effect  and 
gives  a  benefit  both on  response  and  survival.
30,37  A 
potential explanation for this finding may be that the 
use  of  antiretroviral  therapy  can  restore  immune 
surveillance  allowing  for  more  efficient  anti-cancer 
effect.
38 
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Prognostic Factors. Since the introduction of cART, 
the  prognosis  of  patients  with  HIV-associated 
aggressive lymphoma who receive optimal therapy has 
markedly improved, and now the outcome is near the 
same  of  the  HIV-negative  counterpart.  In  general, 
CD4+ cell counts >200 cells/mm
3 and low IPI scores 
are  independent  positive  prognostic  factors.
10,14  In 
patients on effective cART (i.e. undetectable viral load, 
high  CD4,  low  incidence  of  comorbidities),  HIV-
related scores are less important prognostic factors than 
lymphoma  related  features  (i.e.  histology,  tumor 
burden, LDH, performance status).
20 The prognosis of 
HIV-associated  PBL  remains  poor.  In  the  recent 
literature,  the  median  progression-free  (PFS)  and 
overall survival (OS) ranged between 6-7 months and 
11-13  months  respectively,  without  statistical 
difference  between  patients  treated  with  CHOP  or 
CHOP-like  regimens  and  more  intensive  therapy.
15 
However, recently a trend for higher response rates and 
longer OS have been reported with cases of long-term 
survivors reported in the literature.
9,39    Several factors 
affecting  outcome  are  reported  in  the  literature; 
however,  the  most  important  are  achieving  complete 
remission,  performance  status,  clinical  stage,  MYC 
gene  rearrangements,  and  aaIPI.
39  Furthermore, 
extended  and  destructive  masses  at  diagnosis  and 
comorbidities might confer an adverse prognosis. 
 
Differences between HIV-positive and negative PBLs. 
While data on HIV-negative PBLs patients are sparse, 
several  differences  have  been  identified.
4,5  HIV-
negative  PBL  occurs  in  older  patients  and  affects 
relatively  more  females.  HIV-negative  PBL  is  much 
more  heterogeneous  in  terms  of  stage  at  time  of 
diagnosis with extra-oral involvement being reported at 
a higher frequency.
9 Immunosuppression is the major 
risk factor for development of HIV-negative PBL, with 
post-transplant lymphoproliferative disease comprising 
nearly half of the reported cases. In a literature review, 
HIV-negative  PBL  showed  to  have  worse  outcome 
than patients with HIV-positive PBL with a median OS 
of  nine  months;  CR  after  induction  chemotherapy 
being  the  only  prognostic  factor  associated  with 
improved outcomes.
40 
 
Pediatric cases. Although the majority of patients are 
adults, PBL has also been reported in pediatric HIV-
infected patients.
4,5 A literature review identified only 
17 cases. The median age was ten years (range 2-17), 
>80% with advanced stage at presentation and jaw/oral 
cavity  as  the  most  common  site  of  initial  disease.
41 
However, extranodal locations (e.g. skin, vulva, spine, 
scalp) have also been reported. Prognosis is, usually, 
poor  with  two reported long-term  survivors  (3.5 and 
eight years). 
41,42.   
 
Conclusions. HIV-associated PBL is an aggressive and 
rare subtype of NHL with an aggressive clinical course 
and poor outcomes. The current knowledge on this rare 
lymphoma is described in this review and summarized 
for rapid consultation in Table 1. Finally, the evidence 
supporting all the strategies reported here arises from 
single-center  series  and  reviews  and  not  from 
prospective  randomized  trials.  Hence,  due  to  the 
scarcity of data on this subtype of NHL and until more 
definitive evidence become available, the diagnosis and 
management of HIV-positive PBL patients should be 
performed in specialized centers.   
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Table 1. Key Points on HIV-associated Plasmablastic lymphoma
  HIV-associated PBL is an AIDS-defining cancer, classified by WHO as a distinct entity of aggressive DLBCL. 
  Less than 250 cases published to date, 17 in the pediatric population. 
  Pathogenesis related to immunodeficiency, chronic immune stimulation, oncogenic herpesvirus as EBV. 
  Clinical: rapid growing destructive disease mainly of the oral cavity, frequently also extraoral extranodal sites. 
  Diagnosis requires tissue mass or lymph node biopsy. Core needle od fine needle biopsy for difficult access sites 
  Immunophenotype usually CD45, CD20, CD79a negative and CD38, CD138, MUM1 positive, EBER  and KI67 >80% 
  Frequently diagnosed with low CD4+ and high viral load. Recently also reported  in effective cART and high CD4. 
  Treat with regimen more intensive than CHOP, consider intensification with ABMT in CR1 for fit patients. 
  Rituximab not useful (CD20-), Bortezomib used at case report level, with transient response. 
  CNS prophylaxis mandatory. 
  Use of cART recommended during chemotherapy. Keep in mind possible overlapping toxicity. 
  For refractory/relapsed patients consider palliative therapy, chemosensitive disease intensification+ABMT or new drugs  
  Factors affecting outcome: achieving complete remission, PS, Clinical stage, MYC , IPI. 
  Median PFS ranges 6-7 months; Median OS ranges 11-13 months. 
  Long term survivor reported, mostly in pediatric patients. Mediterr J Hematol Infect Dis 2014; 6: Open Journal System   
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